Philippines vs Zambia: Average cost of drugs for extensively drug-resistant tuberculosis
Philippines
282 constant 2022 US$
in 2024
Zambia
600 constant 2022 US$
in 2024
Philippines rank
52nd
Zambia rank
49th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Philippines
- Zambia
How they compare
Zambia currently reports 600 constant 2022 US$ against 282 constant 2022 US$ in Philippines, a difference of 318 constant 2022 US$.
That makes Zambia's figure about 2.1 times Philippines's.
The two have swapped places 1 time across 6 shared years of data; in 2018 it was Philippines ahead.
Philippines ranks 52nd and Zambia ranks 49th of 56 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Philippines | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,436 constant 2022 US$ | 6,240 constant 2022 US$ | 3,196 constant 2022 US$ | Philippines |
| 2020s | 3,710 constant 2022 US$ | 3,210 constant 2022 US$ | 500.25 constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Philippines or Zambia?
- Zambia, at 600 constant 2022 US$ against 282 constant 2022 US$ in Philippines as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Philippines and Zambia?
- 318 constant 2022 US$, with Zambia ahead.
- How many years of comparable data are there for Philippines and Zambia?
- 6 years are reported by both, from 2018 to 2024.
- How do Philippines and Zambia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Philippines ranks 52nd and Zambia ranks 49th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.